At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 120 enrolled
Drug / intervention
CSL's 2010/2011 Formulation of Enzira® Vaccinebiological
Likely dose
CSL's 2010/2011 Formulation of Enzira® Vaccine 45 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV, Single-centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2010/2011 Formulation of Enzira® Vaccine in Two Groups of Healthy Volunteers: 'Adults' (Aged 18 to 59 Years) and 'Older Adults' (Aged 60 Years or Older)
In Brief
A Phase 4 clinical trial evaluating CSL's 2010/2011 Formulation of Enzira® Vaccine for Influenza. Completed, enrolled 120 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether the 2010/2011 Formulation Enzira vaccine is safe and elicits an immune response to seasonal influenza in healthy adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2010
Enrollment StartMay 2010
Primary CompletionMay 2010
TodayJul 2026
First PostedApr 30, 2010
Enrollment StartMay 1, 2010
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 16.2 years ago
Interventions
CSL's 2010/2011 Formulation of Enzira® Vaccinebiological
45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0